The Association Between Traumatic Brain Injury and Cardiovascular Disease: A Systematic Review and Meta-Analysis.

J Head Trauma RehabilMar 19, 2026 (epub)
Clinical ResearchCardiologyNeurology

Sarah Zeyad Mahasin, Bhaskar Thakur, Patricia Champagne et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review and meta-analysis examined observational studies comparing cardiovascular disease (CVD) in adults with and without traumatic brain injury (TBI). The review included 21 studies; 18 studies, comprising 3,954,962 participants, contributed to meta-analysis. In unadjusted analyses, TBI was associated with higher odds of any CVD (OR 1.78, 95% CI 1.39-2.29), as well as several specific cardiovascular outcomes. Adjusted findings were consistent for coronary artery disease, cardiac death, hypertension, and heart failure. No association was found with heart failure in the unadjusted analysis.

Key findings

  • TBI was associated with higher odds of any CVD in unadjusted analysis (OR 1.78, 95% CI 1.39-2.29).
  • Unadjusted analyses found higher odds of CAD (OR 1.40, 95% CI 1.20-1.63) and arrhythmia (OR 1.42, 95% CI 1.12-1.80) after TBI.
  • Cardiac death was more frequent in the TBI group (RR 3.07, 95% CI 2.17-3.98) in unadjusted analysis.
  • No unadjusted association was found between TBI and heart failure (OR 1.16, 95% CI 0.96-1.39).

Why it matters

The findings indicate that cardiovascular conditions may be an important part of the longer-term health burden associated with TBI. The reported associations across several outcomes support attention to cardiovascular health in this population, while the observational evidence does not establish that TBI causes these conditions.

What to keep in mind

The evidence comes from observational studies, and two of the 21 included studies were rated poor quality. Several reported associations were from unadjusted analyses.

Source

Published in J Head Trauma Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.